F;1/Modified site: acetylated amino end (Ala) #status experimental
F;11-105/Domain: cytochrome c homology <CYC>
F;21,24/Binding site: heme (Cys) (covalent) #status predicted
F;25,87/Binding site: heme iron (His, Met) (axial ligands) #status predicted
F;79/Modified site: N6,N6,N6-trimethyllysine (Lys) #status predicted
F;57-74,165-172/Region: cytochrome c binding #status predicted
F;17-59,21-55,31-45/Disulfide bonds: #status predicted
F;121,123,145,148/Binding site: 2Fe-2S cluster (Cys, His, Cys, His) (covalent) #status predicted
F;179-212/Domain: carboxyl-terminal propeptide #link EAG #status predicted <ECP>
F;96-162-165/Cross-link: heme P460 (Lys-Cys-Cys) #status predicted
F;38,90/Active site: Cys, His #status experimental
F;14,17/Binding site: heme (Cys) (covalent) #status experimental
F;1564-1565/Cleavage site: Arg-Ser (thrombin) #status experimental
F;145-147/Cross-link: 5-imidazolinone (Cys-Gly) #status predicted
F;104-107/Disulfide bonds: redox-active #status experimental
F;6-105,112-193/Domain: SH2 #status predicted <SH2>
F;16/Inhibitory site: Arg (chymotrypsin) #status predicted
F;46,47,54,56,59,60,65,66,69,72,75,79/Modified site: gamma-carboxyglutamic acid (Glu) #status experimental
F;24-291/Product: cytochrome c552 #status experimental <MAT>
F;10-15,58-62,90-100/Region: FMN-phosphate binding #status experimental
